YUVEZZI
Launchcarbachol and brimonidine tartrate
NDAOPHTHALMICSOLUTION/DROPS
Approved
Jan 2026
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUVEZZI is a fixed-dose combination ophthalmic solution containing carbachol (a parasympathomimetic agent) and brimonidine tartrate (an alpha-2 adrenergic agonist) delivered as eye drops. The combination targets intraocular pressure reduction and related ophthalmic conditions through dual mechanisms of action. This product represents a novel formulation approach in the glaucoma and ocular hypertension treatment landscape.
Growth16.2 years to LOE
Early-stage launch with established commercial infrastructure and dedicated specialty sales teams suggests aggressive market entry strategy and team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
YUVEZZI launch creates near-term career opportunities primarily in commercial roles, with emphasis on specialty sales, regional leadership, and thought leader engagement across key US markets. The 9 linked job openings indicate active team building in anticipation of product commercialization, offering entry and mid-level advancement prospects in field sales and medical liaison functions.
Thought Leader Liaison (Central)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.